Explore Our Biomarker Menu

Biomarker:

MDM2 (total)

Biological or Clinical Significance:

MDM2 (MDM2 Proto-Oncogene, E3 Ubiquitin Protein Ligase) is a Protein Coding gene. Diseases associated with MDM2 include dedifferentiated liposarcoma and atypical lipomatous tumor. Among its related pathways are PI3K-Akt signaling pathway and PI3K/AKT Signaling in Cancer. Mdm2 is an important negative regulator of the p53 tumor suppressor. Mdm2 protein functions both as an E3 ubiquitin ligase that recognizes the N-terminal trans-activation domain (TAD) of the p53 tumor suppressor and an inhibitor of p53 transcriptional activation. MDM2 promotes tissue inflammation and MDM2 inhibition has potent anti-inflammatory effects in tissue injury.

References:

Analyte:

MDM2 (total)

Matrix:

Status:

Experienced Running

Sensitivity-LLOQ:

Sensitivity-ULOQ:

platform

MSD-ECL

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.